Clinical Trial Update: Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing camrelizumab plus apatinib with hepatic artery infusion chemotherapy (HAIC) versus camrelizumab plus apatinib for hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING